ClinicalTrials.gg
Not yet recruitingNCT04912167PERI-STEMIUpdated Sep 29, 2021

The Effects of Sacubitril-Valsartan vs Enalapril on Left Ventricular Remodeling in ST-elevation Myocardial Infarction

A Phase 3 interventional study of Sacubitril-Valsartan and Enalapril in STEMI, sponsored by West China Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-09-29.

Sponsored by West China Hospital · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2022, 4 years 8 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
376
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 146 studies in ST Elevation Myocardial Infarction with a site in China — 41 open to participants now, 43 under way, 2 of them phase 3. ST Elevation Myocardial Infarction · China.

Planned enrollment
43rd of 97
376 · median 320
Started
2021
with 12 others
Phase 3
9 of 146
2 open now
Primary completion
2022-03
later than 0 of 42 live
Registered
84th of 146
by date

Among the 146 studies in ST Elevation Myocardial Infarction with a site in China, this one is the 43rd largest by planned enrollment of the 97 interventional ones that give a count, is one of 13 that started in 2021, is one of 9 in phase 3, reaches primary completion later than 0 of the 42 other live ones, and was the 84th registered.

ST Elevation Myocardial Infarction

851 studies on the registry are indexed under ST Elevation Myocardial Infarction; 198 are open to participants now.

Browse ST Elevation Myocardial Infarction studies →

Open to participants now

41 of the 146 studies in ST Elevation Myocardial Infarction with a site in China are open now. Recruiting first, the newest first:

36 more — sign in →

All 41 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 122 ST Elevation Myocardial Infarction studies recruiting now, 76 (62%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 146 studies in ST Elevation Myocardial Infarction with a site in China, or all of them as a file.
02

Study summary

The primary objective of the PERI-STEMI trial is to assess whether sacubitril-valsartan is more effective in preventing adverse LV remodeling for patients with ST-elevation myocardial infarction (STEMI) than enalapril.

03

Conditions studied

  • STEMI

Keywords

  • ST-elevation myocardial infarction (STEMI)
  • cardiovascular magnetic resonance (CMR)
  • angiotensin receptor neprilysin inhibitor (ARNI)
  • angiotensin-converting enzyme inhibitor (ACEI)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 18 - 75 years old
  • First-time ST-segment elevation myocardial infarction based on the newest ESC guidelines
  • Timely primary percutaneous coronary intervention within 12 hours from onset
  • Written acquired

Exclusion criteria

Exclusion Criteria:

  • Known history of or persistent clinical chronic heart failure prior to randomization
  • Previous use of ARNI, or intolerance or to study drugs including ARNI or ACEI
  • History of significant chronic coronary obstruction and adverse ventricular remodeling
  • History of any cardiomyopathy, valvular heart disease, congenital heart disease, stent or CABG, or planned open-heart surgery within 3 months
  • History of hepatic impairment or history of cirrhosis with evidence of portal hypertension
  • History of chronic renal dysfunction, or \< 30 ml/min/1.73 m2
  • History of and with a life span less than one year
  • Patients with a known history of angioedema related to previous ACEIs/ARB therapy.
  • With contraindication to MRI examination (pacemaker and claustrophobia) or cannot finish breath-holding when lying on the examination bed
  • Pregnancy or nursing women
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
376 participants (estimated)

Study arms

  • Experimental
    ARNI-Sacubitril-Valsartan

    patients randomized to angiotensin receptor neprilysin inhibitor (ARNI) group will receive 2 doses of angiotensin receptor blocker (ARB) to ensure a minimum 36-hour washout period prior to initiation of ARNI therapy, and then be started with the first dose or sacubitril-valsartan.

    Drug: Sacubitril-Valsartan · Drug: Valsartan

  • Active comparator
    ACEI-Enalapril

    patients randomized to angiotensin-converting enzyme inhibitor (ACEI) group will directly start with the first dose of enalapril

    Drug: Enalapril

Interventions

  • DrugSacubitril-Valsartan

    After initiation of the treatment of sacubitril/valsartan, the dose of the medicine will be titrated to a target level based on the systolic blood pressure of the patients. (24/26 mg, 49/51 mg and 97/103 mg, twice daily)

  • After initiation of the treatment of enalapril, the dose of the medicine will be titrated to a target level based on the systolic blood pressure of the patients. (2.5 mg, 5 mg, and 10 mg,twice daily)

  • For patients who were previously treated with ACEI and receiving the last dose of that agent during the last 36 hours prior to randomization, Valsartan (VAL489) 40 mg and 80 mg tablets, two doses for 1 day was used.

06

What researchers measure

Primary outcomes

  1. LV remodeling index on CMR

    change of the indexed LV mass (Δ LVmassi) from baseline to 6-month follow-up on CMR

    Time frame: 6 months

Secondary outcomes

  1. left ventricular (LV) ejection fraction

    left ventricular ejection fraction indexes at the 6-month CMR.

    Time frame: 6 months

  2. global peak LV longitudinal strain

    global peak LV longitudinal strain at the 6-month CMR.

    Time frame: 6 months

  3. myocardial fibrosis

    extracelluar volume measured through T1 mapping sequence at the 6-month CMR.

    Time frame: 6 months

  4. Time to the first occurrence of a composite endpoint of adverse clinical events

    including all deaths (cardiac death vs non-cardiac death), non-fatal myocardial re-infarction, hospitalization for worsening heart failure or need for advanced HF therapies (hospital stay \> 24 hours)(e.g., intravenous use of inotropes, left ventricular assist device placement, or cardiac transplantation)

    Time frame: up to approximately 60 months

07

Study locations

1 site
08

References and documents

Publications

  • Diao K, Wang D, Chen Z, Wu X, Ma M, Zhu Y, Zhang L, Wang H, Wang M, He S, Li C, Deng Q, Yan T, Wu T, Tang L, Huang B, Sun J, He Y. Rationale and design of a multi-center, prospective randomized controlled trial on the effects of sacubitril-valsartan versus enalapril on left ventricular remodeling in ST-elevation myocardial infarction: The PERI-STEMI study. Clin Cardiol. 2021 Dec;44(12):1709-1717. doi: 10.1002/clc.23744. Epub 2021 Oct 20. PubMed 34668596 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2021; primary completion for Mar 2022, 4 months later.

Of 38 phase 3 interventional studies under ST Elevation Myocardial Infarction, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 58. This study's planned 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2021
First posted
Jun 3, 2021
StartEst.
Nov 2021
Primary completionEst.
Mar 2022
CompletionEst.
Jun 2026
Last update
Sep 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04912167
Responsible party
Yong He (Professor, West China Hospital) — Principal investigator
First posted
Jun 3, 2021
Start date
Nov 2021 (estimated)
Primary completion
Mar 2022 (estimated)
Completion
Jun 2026 (estimated)
Last update
Sep 29, 2021

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valsartan

Start the discussion